SCHEMBL19852893

SCHEMBL19852893

NC(=O)CN1CCC2(CCCN2C(=O)[C@@H](N)CS)C1=O

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.35
BDKRB2 P30411 1/20 0.31
GRIN2B Q13224 1/20 0.30
GRIN2C Q14957 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852896 0.89 TSHR (0.36) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL19852941 0.87 TSHR (0.35) TSHRBDKRB2
SCHEMBL19852844 0.84 TSHR (0.38) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL24338625 0.82 GRIN2B (0.38) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL24620404 0.81 GRIN2B (0.34) BDKRB2GRIN2BGRIN2C
SCHEMBL24620375 0.80 DPP4 (0.37) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL19852894 0.80 GRIN2B (0.36) GRIN2BGRIN2C
SCHEMBL19852817 0.79 TSHR (0.41) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL19852949 0.78 TSHR (0.40) TSHRBDKRB2GRIN2BGRIN2C
SCHEMBL24339477 0.78 GRIN2B (0.35) GRIN2BGRIN2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312591-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2023-10-05 US disclosed
US-20230312591-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2023-10-05 US disclosed
US-11530223-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-12-20 US disclosed
US-20220220119-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2022-07-14 US disclosed
US-11299495-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-04-12 US disclosed
WO-2018026779-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299495-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A TSHR 1842/4885BDKRB2 453/4885GRIN2B 5/4885
US-11530223-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A TSHR 1842/4885BDKRB2 453/4885GRIN2B 5/4885
US-20220220119-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A TSHR 1842/4885BDKRB2 453/4885GRIN2B 5/4885
US-20230312591-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A TSHR 1842/4885BDKRB2 453/4885GRIN2B 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.